You are here: Industry Insights > Evotec

News List

Evotec and Sartorius Partner with Curexsys contractpharma
December 10, 2020
Evotec SE and the life science company Sartorius have entered into a partnership with the recently established Curexsys GmbH, a Goettingen, Germany-based technology company specializing in the emerging field of therapeutic exosomes.
Evotec and Bioaster Partner contractpharma
September 15, 2020
Evotec SE and Bioaster Technological Research Institute have entered into a partnership to advance research for infectious diseases. Bioaster is a technology and innovation hub located in Lyon, France that has created a new model to address the ...
Evotec and Novo Nordisk Form Strategic Alliance contractpharma
August 19, 2020
Evotec SE and Novo Nordisk have announced a strategic collaboration on the discovery and development of innovative therapeutics for patients with chronic kidney disease.
Just - Evotec Biologics Wins COVID-19 DoD Contract contractpharma
July 23, 2020
To develop and manufacture monoclonal antibodies (mAbs) for treatment and/or prevention of COVID-19.
Evotec, leon-nanodrugs Enter Nanomedicine Pact contractpharma
April 20, 2020
Evotec makes strategic investment in leon by leading the company's Series B funding round.
Evotec and Bayer to develop polycystic ovary syndrome drug candidates pharmaceutical-technology
January 13, 2020
German firms Evotec and Bayer have agreed to expand their alliance to develop drug candidates for polycystic ovary syndrome (PCOS).PCOS is an endocrine disorder associated with metabolic dysfunction that can cause pregnancy complications and infertility.
Evotec, Takeda Enter Multi-Year Drug Discovery Pact contractpharma
September 25, 2019
Evotec SE has entered a strategic, multi-year drug discovery collaboration with Takeda Pharmaceutical Co. Ltd. to establish at least five drug discovery programs with the goal of Evotec delivering clinical candidates ...
Partnership with Evotec to Advance Nosopharm’s Lead Candidate contractpharma
July 17, 2019
NOSO-502 could be first novel antibiotic class against Enterobacteriaceae infections to enter clinics in forty years.
Evotec spin-off to develop cancer drugs using DDR pathway pharmaceutical-technology
July 10, 2019
Evotec has formed spin-off company Breakpoint Therapeutics to focus on the development of its DNA damage response (DDR) portfolio.
Nosopharm and Evotec to develop antibiotic drugs pharmaceutical-technology
July 08, 2019
Nosopharm has partnered with German drug discovery and development firm Evotec to advance NOSO-502 into clinical development.

Previous page 1 2 3 4 Next page